Skip to content


View from the field
Polaris is a tool that allows parents to track every stage of their child’s treatment against leukemia.

Leukemia is a common childhood cancer. With the right medicines and medical care, most children can be cured, but the treatment is complex and long (often lasting over two yrs). Servier teamed up with European Society for Paediatric Oncology to develop POLARIS, a tool that allows parents to follow every step of their child’s treatment on their smartphone or desktop. The treating physician links parents to a secure site where they access the treatment information. The information is “translated” into an easy-to-understand graphic language that makes it easy for parents and even young patients to follow their treatment plan day-by-day. They can also access additional information about leukemia, specific medical procedures, and information to support recovery.

Manette LE GRANGE, PhD Corporate Social Responsibility Project Lead

Working toward equal access to medicines

Significant progress in medicine has made it possible to treat and control illnesses that would previously have been fatal. Yet, one third of the world’s population cannot access these essential treatments. We consider why, and what can be done.

View from the field
The idea behind YOSR is to make our innovative treatments both accessible and affordable

YOSR, which means “ease” in Arabic, is the name of our patient assistance program. It has been specially designed to help people struggling to pay for their annual treatment after being diagnosed with hypertension, heart failure or colorectal cancer. The program was launched in the United Arab Emirates, Oman and Kuwait, where many patients do not have health insurance or sufficient coverage. Developed in collaboration with an insurance partner and the health ministries of the countries involved, the idea behind YOSR is to make our innovative treatments both accessible and affordable.

Abdullah AL-BOW Business Excellence Director, Servier Middle East

Servier in action

Fighting children’s cancer

Through its first iconic CSR project, Servier seeks to contribute to achieving the World Health Organization’s goal to increase the survival rate of children with cancer globally to at least 60% by 2030. The success of the project requires progress in three areas—improving access to existing treatments, investing in R&D, and supporting patients, their friends, and health care professionals.

A new world of work

A revolution is taking place in the world of work, prompting employees to reassess their priorities and expectations. In order to continue to attract and retain talent, companies must boost their efforts and bolster their value proposition.

View from the field
What I really like about my job is that it is useful and practical.

At Servier, I’m working on systemic scleroderma, a rare autoimmune diseases that primarily affects middle-aged women, leaving them with an estimated 11 years to live on average. There is currently no treatment to cure the disease. Servier is committed to combating rare diseases. My job is to try to understand how the disease works by analyzing samples from patients. The idea is to assess potentially promising drug candidates to treat systemic scleroderma. What I really like about my job is that it is useful and practical. And most importantly, what we do brings hope to patients!

Selena BOUFFETTE PhD student and researcher at Servier

Servier in action


The number of HR labels obtained in 2023, including 22 subsidiaries certified Great Place to Work and 7 certified Top Employer

66 %

of employees feel engaged (up 5% on 2022)

A “MAP” to Servier 2030!

100% of employees took part in the “MAP” initiative, an interactive experience that enabled managers and their teams to understand and talk about the Servier 2030 strategy. This forum for discussion was greatly appreciated, reflecting our employees top priority—being part of a team.

Download the 2022-2023 Integrated Annual Report

Download the 2022-2023 Integrated Annual Report